Xuejing Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xuejing Lin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Changqing Su
Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & Institute, Second Military Medical University, Shanghai, 200438, China
3 shared publications - Zhangxiao Peng
Navy Military Medical University
2 shared publications Ai-Li Wang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, 507 Zhengmin Road, Shanghai 200433, P. R. China
1 shared publication- Bin Sun
Center for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication Chunying Liu
Department of Molecular Oncology, Eastern Hepatobiliary Surgical Hospital & National Center of Liver Cancer, Second Military Medical University, Shanghai 200438, China
1 shared publication- Chunying Liu
National Center for Liver Cancer, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, P. R. China
1 shared publication
Latest Publications
- Open Access
- 21 March 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (8) , 1905-1915
MUC15 acts as a tumor suppressor gene which correlates with prognosis and immune infiltration in esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC), as a common malignant tumor of the digestive system, has been a challenge in improving and prolonging the postoperative survival of patients. This study aims to identify novel biomarkers that can guide the clinical diagnosis and treatment by using bioinformatics methods. The RNA-seq data and corresponding clinical data of ESCC were downloaded from the TCGA and GEO database. Weighted co-expression network analysis (WGCNA) was used to identify candidate biomarkers. The LASSO analysis was performed to classify the biomarkers. ROC curve and AUC were used to evaluate the sensitivity and specificity of biomarkers. CIBERSORT was applied to estimate the relative abundances of immune cell types through gene expression profiling. Univariate and multiple Cox regression were performed to screen out prognostic factors. MUC15, which abnormally expressed in different physiological processes and participates in inhibiting or promoting function in different types of tumors, was selected of candidate biomarker. Finally, we validated the expression of MUC15 in ESCC tissues and its inhibitory effect on cell function through in vitro and in vivo experiments. In conclusion, we identified MUC15 could serve as a tumor suppressor gene and may become a promising candidate for individualized clinical diagnosis and treatment of ESCC.
- 21 March 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (8) , 1905-1915
Open AccessMUC15 acts as a tumor suppressor gene which correlates with prognosis and immune infiltration in esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC), as a common malignant tumor of the digestive system, has been a challenge in improving and prolonging the postoperative survival of patients. This study aims to identify novel biomarkers that can guide the clinical diagnosis and treatment by using bioinformatics methods. The RNA-seq data and corresponding clinical data of ESCC were downloaded from the TCGA and GEO database. Weighted co-expression network analysis (WGCNA) was used to identify candidate biomarkers. The LASSO analysis was performed to classify the biomarkers. ROC curve and AUC were used to evaluate the sensitivity and specificity of biomarkers. CIBERSORT was applied to estimate the relative abundances of immune cell types through gene expression profiling. Univariate and multiple Cox regression were performed to screen out prognostic factors. MUC15, which abnormally expressed in different physiological processes and participates in inhibiting or promoting function in different types of tumors, was selected of candidate biomarker. Finally, we validated the expression of MUC15 in ESCC tissues and its inhibitory effect on cell function through in vitro and in vivo experiments. In conclusion, we identified MUC15 could serve as a tumor suppressor gene and may become a promising candidate for individualized clinical diagnosis and treatment of ESCC.
- Open Access
- 16 November 2020
- Published by IntechOpen
Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
Extracellular vesicles (EVs) can deliver many types of drugs with their natural source material transport properties, inherent long-term blood circulation capabilities and excellent biocompatibility, and have great potential in the field of drug carrier. Modification of the content and surface of EVs according to the purpose of treatment has become a research focus to improve the drug load and the targeting of EVs. EVs can maximize the stability of the drugs, prevent immune clearance and achieve accurate delivery. Therefore, EVs can be described as \" stealth transport aircrafts \" for drugs. This chapter will respectively introduce the application of natural EVs as cell substitutes in cell therapy and engineered EVs as carriers of nucleic acids, proteins, small molecule drugs and therapeutic viral particles in disease treatment. It will also explain the drug loading and modification strategies of EVs, the source and characteristics of EVs. In addition, the commercialization progress of EVs drugs will be mentioned here, and the problems in their applications will be discussed in conjunction with the application of EVs in the treatment of COVID-19.
- 16 November 2020
- Published by IntechOpen
Open AccessExtracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
Extracellular vesicles (EVs) can deliver many types of drugs with their natural source material transport properties, inherent long-term blood circulation capabilities and excellent biocompatibility, and have great potential in the field of drug carrier. Modification of the content and surface of EVs according to the purpose of treatment has become a research focus to improve the drug load and the targeting of EVs. EVs can maximize the stability of the drugs, prevent immune clearance and achieve accurate delivery. Therefore, EVs can be described as \" stealth transport aircrafts \" for drugs. This chapter will respectively introduce the application of natural EVs as cell substitutes in cell therapy and engineered EVs as carriers of nucleic acids, proteins, small molecule drugs and therapeutic viral particles in disease treatment. It will also explain the drug loading and modification strategies of EVs, the source and characteristics of EVs. In addition, the commercialization progress of EVs drugs will be mentioned here, and the problems in their applications will be discussed in conjunction with the application of EVs in the treatment of COVID-19.
- 1 November 2017
- Published by Elsevier in Journal of Chromatography B
- Vol. 1068-1069, 343-351
A rapid quantitative analysis of bile acids, lysophosphatidylcholines and polyunsaturated fatty acids in biofluids based on ultraperformance liquid chromatography coupled with triple quadrupole tandem massspectrometry
- 1 November 2017
- Published by Elsevier in Journal of Chromatography B
- Vol. 1068-1069, 343-351
A rapid quantitative analysis of bile acids, lysophosphatidylcholines and polyunsaturated fatty acids in biofluids based on ultraperformance liquid chromatography coupled with triple quadrupole tandem massspectrometry
- Open Access
- 13 May 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 10888-10906
Potential Anti-Cancer Activities and Mechanisms of Costunolide and Dehydrocostuslactone
Costunolide (CE) and dehydrocostuslactone (DE) are derived from many species of medicinal plants, such as Saussurea lappa Decne and Laurus nobilis L. They have been reported for their wide spectrum of biological effects, including anti-inflammatory, anticancer, antiviral, antimicrobial, antifungal, antioxidant, antidiabetic, antiulcer, and anthelmintic activities. In recent years, they have caused extensive interest in researchers due to their potential anti-cancer activities for various types of cancer, and their anti-cancer mechanisms, including causing cell cycle arrest, inducing apoptosis and differentiation, promoting the aggregation of microtubule protein, inhibiting the activity of telomerase, inhibiting metastasis and invasion, reversing multidrug resistance, restraining angiogenesis has been studied. This review will summarize anti-cancer activities and associated molecular mechanisms of these two compounds for the purpose of promoting their research and application.
- 13 May 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 10888-10906
Open AccessPotential Anti-Cancer Activities and Mechanisms of Costunolide and Dehydrocostuslactone
Costunolide (CE) and dehydrocostuslactone (DE) are derived from many species of medicinal plants, such as Saussurea lappa Decne and Laurus nobilis L. They have been reported for their wide spectrum of biological effects, including anti-inflammatory, anticancer, antiviral, antimicrobial, antifungal, antioxidant, antidiabetic, antiulcer, and anthelmintic activities. In recent years, they have caused extensive interest in researchers due to their potential anti-cancer activities for various types of cancer, and their anti-cancer mechanisms, including causing cell cycle arrest, inducing apoptosis and differentiation, promoting the aggregation of microtubule protein, inhibiting the activity of telomerase, inhibiting metastasis and invasion, reversing multidrug resistance, restraining angiogenesis has been studied. This review will summarize anti-cancer activities and associated molecular mechanisms of these two compounds for the purpose of promoting their research and application.